Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy
in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK
Pathway–Mutant Acute Lymphoblastic Leukemia
A study of the safety and efficacy of ruxolitinib with routine chemotherapy for children with leukemia with specific genetic changes.
A diagnosis of leukemia, specifically de novo high B-ALL with eligible genetic changes. Age must be greater than 1 year old and less than or equal to 21 years old at leukemia diagnosis. Have completed an acceptable induction therapy either on study or by hospital standard of care.
Exclusion Criteria:
Had any other chemotherapy before induction therapy, with exceptions. Down Syndrome.
Women In Steady Exercise Research - Neoadjuvant Exercise Trial
The primary purpose of this pilot study is to determine whether breast cancer patients whom elect to undergo cardiotoxic neoadjuvant chemotherapy can be enrolled and retained in a 6 month at home aerobic exercise training study. Using a randomized controlled trial approach, we will examine the safety and efficacy of a well monitored moderate-to-high intensity aerobic training program completed at home in breast cancer patients receiving neoadjuvant chemotherapy. In addition to assessing safety and efficacy of the program, we will assess intervention effects on cardiopulmonary fitness, cardiac function, and tumor response.
Stage 1-3 breast cancer Scheduled to start neoadjuvant chemotherapy Sedentary No heart disease
Exclusion Criteria:
Stage 4 breast cancer Heart disease Non-English speaking
Cancer
Email this study information to me
Contact the study team
Show all
3
locations
Study Locations
Hide all locations
Location
Greater Philadelphia Area, PA
Harrisburg, PA
Hershey, PA
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium(BTCRC-GU16-043) (PSCI 18-008)
This study is being done to test the safety of combining durvalumab with guadecitabine. It will also measure the percentage of patients whose tumor shrank after receiving durvalumab in combination with guadecitabine. Participants with kidney cancer that has spread to other parts of the body, also known as 'metastatic kidney cancer' will be recruited to participate.
Histological diagnosis of clear cell renal cell carcinoma (pure or mixed) with radiologic or histologic evidence of metastatic disease Prior cancer treatment must be completed at least 14 dats prior to study registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to Grade 1 or less baseline ECOG Performance Status 0-1 within 28 days prior to registration Demonstrate adequate organ function based on necessary screening labs to be obtained within 28 days prior to registration Females of childbearing potential must have a negative serum pregnancy test within 28 days prior to registration
Exclusion Criteria:
Active infection requiring systemic therapy Brain metastases or spinal cord compression Pregnant or breastfeeding Treatment with any investigational drug within 14 days prior to study registration Current or prior use of immunosuppresive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiologic doses
Relapsed or refractory B-cell or T-cell ALL after multi-agent chemotherapy(≥ 5% marrow lymphoblasts, assessed by morphology and flow cytometry ECOG performance status 0-2 Creatinine clearance of at least 50 mL/min within 7 days prior to first dose of study agent Adequate liver function with AST/ALT less than 3X upper limit of normal and total bilirubin less than 2 mg/dL within 7 days prior to first dose of study agent Circulating WBC count must not be above 20 x10^9/L within 7 days prior to first dose of study agent
Exclusion Criteria:
Pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol Evidence of isolated extramedullary relapse (i.e., testicular or CNS) Serious medical or psychiatric illness that in the opinion of the primary investigator is likely to interfere with study participation may not be enrolled Poorly controlled HIV, or CD4 < 400. HIV positive patients are allowed on this study if they have a CD4 count greater than or equal to 400, and are on a stable antiviral regimen Patients with NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia may not be enrolled
Site for Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
To assess whether the addition of 6 cycles of cabazitaxel to
abiraterone acetate in patients with CRPC that have previously
received docetaxel and ADT for HSPC can improve PFS compared to
abiraterone acetate alone.
Age ≥ 18 years Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate). Previous chemotherapy with at least 3 cycles of docetaxel for hormone-sensitive metastatic prostate cancer. Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (CT/MRI of abdomen/pelvis, bone scintigraphy or NaF PET/CT). Ability to swallow abiraterone acetate tablets as a whole.
Exclusion Criteria:
Any prior chemotherapy or AR-directed therapy for CRPC, (e.g. docetaxel, cabazitaxel, mitoxantrone, abiraterone Pure small cell or other variant (non-adenocarcinoma) prostate cancer histology for which treatment with abiraterone would not be considered appropriate. Patients may not be receiving other therapeutic investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy. Any medical condition for which prednisone (corticosteroid) is contraindicated. Active infection requiring treatment with antibiotics.
A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).
This is a drug study that will examine the drug Ribociclib with endocrine therapy versus just endocrine therapy in patients with early breast cancer.
Patient with histologically confirmed unilateral primary invasive adenocarcinoma of the breast with a date of initial cytologic or histologic diagnosis within 18 months prior to randomization Patient has breast cancer that is positive for ER and/or PgR Patient has HER2-negative breast cancer defined as a negative Patient has available archival tumor tissue from the surgical specimen, for submission to a central laboratory. If indicated, patient has completed adjuvant and/or neoadjuvant chemotherapy according to the institutional guidelines
Exclusion Criteria:
Patient has received any CDK4/6 inhibitor Patient has received prior treatment with tamoxifen, raloxifene or AIs Patient has received prior treatment with anthracyclines at cumulative doses of 450 mg/m² or more for doxorubicin, or 900 mg/m² or more for epirubicin. h a known hypersensitivity to any of the excipients of ribociclib and/or ET ( Patient with distant metastases of breast cancer beyond regional lymph nodes
Site for EA9161: A Randomized Phase III Study of the addition of
Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib
and Obinutuzumab in Untreated Younger Patients with
Chronic Lymphocytic Leukemia (CLL)
The is a drug study to compare the progression free
survival of the three drug combination Ibrutinib-Obinutuzumab-Venetoclax (IOV) to Ibrutinib-Obinutuzumab (IO) in untreated CLL patients younger than 70 years of age.
Diagnosis of CLL according to the NCI/IWCLL criteria or SLL according to the WHO criteria Negative FISH analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy Age ≥ 18 years and < 70. ECOG performance status between 0-2. Life expectancy of ≥ 12 months.
Exclusion Criteria:
No deletion of 17p13 on cytogenetic analysis by FISH No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment. No current use of corticosteroids. No previous autoimmune complications No other active primary malignancy
Histologic documentation of women or men with HER2 negative breast carcinoma and free of recurrence. Prior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined by the treating physician, is allowed. Age > 18 and < 70 years of age. ECOG performance status 0-2. Patients with a prior history of gastric/duodenal ulcers documented on endoscopy can be enrolled as long as the ulcers did not cause bleeding requiring a blood transfusion/major intervention.
Exclusion Criteria:
No history of GI bleeding requiring a blood transfusion, endoscopic or operative intervention. No history of any prior stroke (hemorrhagic or ischemic). No concurrent anticoagulation with warfarin, heparin/heparin analogues, clopidogrel, direct thrombin inhibitors, or direct factor XA inhibitors. No history of atrial fibrillation or myocardial infarction. No history of grade 4 hypertension, defined as hypertension resulting in lifethreatening consequences
Our goal is to better understand how exercise impacts patients with liver cancer in order to identify treatments that can improve outcomes and access to liver transplantation.
Using Exercise to Relieve Arthralgia (Joint Pain) and Improve AI Adherence in Older Survivors (REJOIN): A Pilot Study
Briefly, the purpose of this study is to use a self-management approach (combining education and exercise) to help older breast cancer survivors manage joint pain, a common side effect of aromatase inhibitors (AIs), a medication used to reduce hormones that might increase risk of recurrence and mortality following primary cancer treatment. We believe that reducing joint pain might help survivors take their medication longer and thus improve survival outcomes, compared to standard care.
Age 65 and older Female Breast Cancer Survivor Preparing to Start AI medication ER+ diagnosis
Exclusion Criteria:
Already taking AI medication (greater than 2 weeks) Gross Cognitive Impairment Recent Joint Surgery Cardiac event/Stroke within last 6 months Not willing to come to HMC for Exercise Sessions
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
This study is to see if venetoclax in combination with bendamustine and rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to examine the side effects, good and bad, associated with this combination .
Must have histologically confirmed (biopsy-proven) diagnosis of mantle cell lymphoma (MCL) Must have measurable or evaluable disease as defined as a lymph node measuring >1.5 cm in any dimension or splenomegaly with spleen >15 cm in craniocaudal dimension ECOG performance status of 0-2 Adequate organ function as measured by the criteria Total Bilirubin ≤ 1.5x upper limit of normal (ULN) or ≤ 3x ULN with documented Gilbert’s syndrome
Exclusion Criteria:
Should not have known evidence of central nervous system (CNS) lymphoma Should not have prior chemotherapy, radiotherapy or immunotherapy for lymphoma Must not have received a prior allogeneic stem cell transplant or solid organ transplant (except for cornea) for any indication Must have no active, uncontrolled infections Must not have active hepatitis B or be chronic carriers of hepatitis B.
Site for Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) (PSCI# 19-079) (S1803)
This study is being done to answer the following questions:
1. Will adding the drug daratumumab/rHuPH20 to the usual maintenance treatment with lenalidomide after stem cell transplant help multiple myeloma patients survive longer?
2. For patients who have no evidence of multiple myeloma in their bone marrow (patients who do not have “minimum residual disease” [MRD-negative]), should maintenance therapy be stopped after 2 years?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your multiple myeloma. The usual approach is defined as care most people get for multiple myeloma.
Patients must have had a confirmed diagnosis of symptomatic multiple myeloma (See Section 4.1) that required systemic induction therapy prior to autologous stem cell transplantation (ASCT). Patients with disease measurable by serum light chain assay alone are eligible (defined as ≥ 100 mg/L on involved light chain). Patients must be ≥ 18 and ≤ 75 years of age at time of registration to Step 1. Patients must have history and physical exam within 28 days prior to registration. Patients must have Zubrod Performance Status ≤ 2.
Exclusion Criteria:
Patients with smoldering myeloma are not eligible Patients must not have any organ involvement by amyloidosis or evidence of amyloidosis related organ dysfunction. Patients must not have progressive disease at any time prior to registration. Patients must not be refractory or intolerant to either lenalidomide or daratumumab/rHuPH20. Patients must not have moderate or severe persistent asthma within the past 2 years and must not have currently uncontrolled asthma of any classification.
A151216-Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (Alchemist)
Purpose of study is to examine lung cancer patients' surgically removed tumors for certain genetic changes and to possibly refer these patients to a treatment study with drugs that may specifically these tumors.
Surgically resected non-small cell lung cancer Pathologic stage IIIA, II (IIA or IIB) or large IB (defined as size ≥4 cm). Tissue available for the required analyses
Exclusion Criteria:
No patients with recurrence of lung cancer after prior resection No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD1/PD-L1/CTLA-4.
Site for A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer (NRG-HN005) (PSCI# 20-011)
The purpose of the first part of this study is to compare the usual treatment of a standard-dose radiation given over 6 weeks with cisplatin chemotherapy to a reduced-dose radiation given over either 6 weeks with cisplatin or 5 weeks with the immunotherapy drug, nivolumab. A lower dose of radiation as compared to the usual radiation treatment dose could be as effective in lengthening the time without your cancer getting worse. Nivolumab with reduced-dose radiation may or may not be as effective in lengthening the time without your cancer getting worse.
This study will help the study doctors find out if this different approach is the same or worse than the usual approach.
Pathologically proven diagnosis of squamous cell carcinoma of the oropharynx Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations P16-positive based on local site immunohistochemical tissue staining Zubrod Performance Status of 0-1 within 14 days prior to registration Only English, Spanish, or French speaking patients are eligible to participate as these are the only languages for which the mandatory dysphagia-related patient reported instrument (MDADI) is available
Exclusion Criteria:
Clinical stages T0; T4; T1-2, N0; or any N2 (AJCC, 8th ed) Recurrent disease Definitive clinical or radiologic evidence of metastatic disease or adenopathy below the clavicles Cancers considered to be from an oral cavity site or the nasopharynx, hypopharynx, or larynx, even if p16-positive, or histologies of adenosquamous, verrucous, or spindle cell carcinomas Carcinoma of the neck of unknown primary site origin (T0 is ineligible, even if p16-positive)
The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
To evaluate the efficacy of the combination of intravenous
administration of VB-111 and paclitaxel compared to
placebo and paclitaxel in patients with platinum resistant
ovarian cancer as measured by Overall Survival (OS).
Histologically confirmed epithelial ovarian cancer and documented disease. Patients must have platinum-resistant disease Patients must have disease that is measurable according to RECIST 1.1 and require chemotherapy treatment. Adequate hematological functions: ANC ≥ 1000/mm3 PLT ≥ 100,000/mm3 PT and PTT (seconds) < 1.2 X ULN. Patients who are anticoagulated do not need to meet criteria for PT and PTT. Patients who are known to carry a BRCA mutation may be enrolled only after (following PARP inhibitor treatment failure, or being intolerant of, or ineligible for PARP inhibitor treatment).
Exclusion Criteria:
Non-epithelial tumors (Carcino-sarcomas are excluded) Ovarian tumors with low malignant potential (i.e. borderline tumors) clear cell carcinomas, grade 1 serous tumors or mucinous tumors. Patients who had evidence of disease progression during or up to 90 days from the last dose of the first line of platinum based therapy Previous ovarian cancer treatment with >5 anticancer regimens. Any prior radiotherapy to the pelvis or whole abdomen.
A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Part 1 (Phase Ib): To determine the safety and ability for subjects to tolerate APG-115 when combined with pembrolizumab, as well as the maximum tolerated dose in subjects with metastatic melanomas or solid tumors.
Part 2 (Phase II): To determine the overall response rate of APG-115 when combined with pembrolizumab in the treatment of patients with unresectable or metastatic melanomas.
Male or non-pregnant, non-lactating female patients age ≥18 years on day of signing the informed consent Histologically confirmed, unresectable or metastatic melanoma, and refractory or relapse after PD1 antibody treatment and ineligible for other standard of care therapy ECOG Performance scale of 0-2 Life expectancy of equal to or greater than 3 months Adequate bone marrow and organ functionAdequate
Exclusion Criteria:
Any prior systemic MDM2-p53 inhibitor treatment Received chemotherapy within 21 days (42 days for nitrosoureas or mitomycin C) prior to first dose. Prior loco-regional treatment with intralesional therapy (e.g. talimogene laherparepvec) for unresectable or metastatic melanoma in the last 6 months prior to start of study treatment. Received hormonal and biologic (<1 half-lives), small molecule targeted therapies or other anti-cancer therapy within 21 days prior to first dose Radiation or surgery within 14 days of study entry, thoracic radiation within 28 days prior to first dose. Has known active central nervous (CNS) metastases and/or carcinomatous meningitis. Or has neurologic instability per clinical evaluation due to tumor involvement of the CNS. Requirement for corticosteroid treatment, with the exception of megestrol, local use of steroid: i.e.: topical corticosteroids, inhaled corticosteroids for reactive airway disease, ophthalmic, intraarticular, and intranasal steroids.
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)(KEYNOTE-867)(MK 3475-867)
This Phase 3 study is to compare the Event Free Survival (EFS) of using SBRT in combination with pembrolizumab and compared to SBRT in combination with placebo. To compare Overall Survival (OS) of using SBRT in combination pembrolizumab and compared to SBRT in combination with placebo.
Has an ECOG Performance Status of 0, 1, or 2. Has previously untreated NSCLC diagnosed by histology or cytology and confirmed as Stage I or IIA NSCLC (AJCC 8th edition) by chest CT and PET scan. Cannot undergo thoracic surgery due to existing medical illness(es) A female is eligible to participate if she is not pregnant and not breastfeeding Is male or female ≥18 years of age
Exclusion Criteria:
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or breast Has received a live vaccine within 30 days prior to the first dose of study drug. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
Site for MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) (S1827) (PSCI# 20-086)
The purpose of this study is to compare the effects of using brain MRIs alone versus brain MRIs plus PCI on the lifespan of patients with small cell lung cancer. The use of brain MRIs alone could reduce side effects of receiving PCI.
This study is hoping to show that monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) is at least as good as the combination of PCI with MRI scans.
There will be about 668 people taking part in this study.
Patient must have a histologically confirmed diagnosis of small-cell lung cancer (SCLC). Patient must have an MRI of the brain performed within 28 days prior to registration. Patient must have Zubrod Performance Status of 0-2 Patient must be ≥ 18 years of age. All adverse events from prior treatment must have resolved to ≤ Grade 2 (CTCAE Version 5.0) prior to randomization.
Exclusion Criteria:
Patient must not have a contraindication to gadolinium contrast administration during MR imaging, such as allergy or insufficient renal function Patient must not have other metastatic malignancies requiring current active treatment. Patient must not have any severe active comorbidities Patient must not have received prior radiotherapy to the brain or whole brain radiotherapy. Patient must not have a contraindication to MR imaging, such as implanted metal devices or foreign bodies
Nurse AMIE for Echo Show: Randomized Control Trial
The Nurse AMIE platform has been modified to work as an Amazon Alexa Skill for use on the Echo Show device. We will recruit women receiving treatment for metastatic breast cancer and randomize them to receive standard treatment (control) or the Nurse AMIE for Echo Show program. Nurse AMIE is a supportive care program for women undergoing chemotherapy and helps them to manage their symptoms. We will test the feasibility of using the Nurse AMIE program as well as its effectiveness at managing symptoms.
Female patient with metastatic breast cancer At least 18 years of age Personal in-home wi-fi access Personal device capable of receiving telephone calls for weekly check-ins Fluent in written and spoken English
Exclusion Criteria:
ECOG Performance Score of >2 Significant medical or psychiatric conditions (beyond breast cancer) Receiving any behavioral intervention Pregnant Life expectancy of less than 6 months
A diagnosis of pediatric cancer of varying types for which there is no known cure or disease that is not responding to treatment. Must be over one year of age at enrollment. Must be less than or equal to 21 years at initial diagnosis. Must have measurable disease by accepted standards. Tumor must be accessible for biopsy.
Exclusion Criteria:
Has received chemotherapy within the last 7 days of biopsy. Has received any radiotherapy to the primary sample site within the last 14 days. Currently taking any other study drug.
Children's Health, Cancer
Email this study information to me
Contact the study team
Show all
1
locations
Study Locations
Hide all locations
Location
Hershey, PA
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma and Medulloblastoma
A study if the safety and effectiveness of nifurtimox in children with neuroblastoma or medulloblastoma, that has returned or is not responding to treatment.
Ages 0-21 years at the time of diagnosis. Diagnosis of neuroblastoma or medulloblastoma. Disease has not responded to previous treatment. Disease is measurable bu accepted tests.
Exclusion Criteria:
Patients who weigh less than 3.5 kg (7.7 lbs). Currently receiving another study drug. Currently receiving other anticancer agents.
A confirmed diagnosis of neuroblastoma. Must be in complete remission (CR). Tests and scans will be required to confirm remission.
Exclusion Criteria:
Patients below the defined minimum of height and weight. Patients who are currently receiving another study drug may not participate. Patients who are currently receiving other anticancer agents may not participate.
Diagnosis of relapsed or refractory leukemia or solid timor. Age 6 months to less than 30 years at enrollment. Must be fully recovered from effects of previous treatment. Life expectancy greater than or equal to 3 months.
Exclusion Criteria:
Prior treatment with carfilzomib. Known allergy to Captisol®. Down syndrome.
Nurse AMIE: A tablet based supportive care platform in Metastatic Breast Cancer (AMIE = Addressing Metastatic Individuals Everyday)
We propose to build and test a software program called Nurse AMIE (Addressing Metastatic Individuals Everyday) to be provided to Stage IV breast cancer patients on an electronic tablet. This program will be tested in 50 Stage IV breast cancer patients who live within the Penn State Cancer Institute’s 28 county catchment area.
Goals of the Nurse AMIE are to regularly assess mental-health, physical health, and other symptom related needs among Stage IV breast cancer patients and to provide appropriate help via videos, weekly calls (face to face, tablet to tablet) with a patient guide at Penn State, and appropriate referrals to phone or in person visits (as needed). The proposed Nurse AMIE software program will allow for the plan of resources (videos, audio files, exercises) to help with many of the common symptoms and challenges experienced by the patients. This is an identified need on the part of both the patients and their medical care teams. Finally, it will also allow patient guides to check in with patients, review responses to surveys, decide whether new or different documents or videos are needed, and connecting the patient to palliative care and other services if additional care is found to be needed.
metastatic breast cancer ECOG<3 English speaking sufficient vision/hearing or family support
Exclusion Criteria:
Medical or psychiatric conditions (beyond breast cancer, its treatment, and its symptoms) that would impair our ability to test study hypotheses (e. g. psychotic disorders, dementia, inability to give informed consent or follow the instruction). Patients who are receiving any other behavioral intervention
Cancer
Email this study information to me
Contact the study team
Show all
1
locations
Study Locations
Hide all locations
Location
Hershey, PA
A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Venous Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (T or B cell) Treated with Pegylated Asparaginase
A study to confirm and expand information on safety and effectiveness of apixaban to prevent blood clots as compared to no prevention treatment in children with newly diagnosed leukemia and lymphoma. This is a randomized study so patients will be selected by chance to be in either the group that receives apixaban or the group that does not receive apixaban.
New diagnosis of leukemia (de novo ALL) or lymphoma (T or B cell). An acceptable planned induction chemotherapy. One year of age and older to less than 18 years of age. Able to take oral medication or have it given through a tube.
Exclusion Criteria:
Had a blood clot in the past 3 months. Known inherited bleeding disorder.
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A study to confirm and expand information on safety and effectiveness of defibrotide compared to best standard care to prevent veno-occlusive disease of the liver in adult and pediatric transplant patients. This is a randomized study so patients will be selected by chance to be in either the group that receives defibrotide or the group that does not receive defibrotide.
Must be older than 1 month of age. Scheduled for a stem cell transplant and be at high risk of veno-occlusive disease. Be at high risk of veno-occlusive disease.
GLNE 007 Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
The purpose of this study is to see if stool or blood can be used to determine whether or not a patient has any colon polyps or colon cancer. This study will compare these biological samples (blood, urine, stool) to any colonoscopy or surgery a patient has to see if the outcome could be predicted.
Adult 18+ Subjects with Colon Cancer or Adenoma OR subjects undergoing colonoscopy screening
Exclusion Criteria:
Inflammatory Bowel Disease HIV/Hepatitis Have had or are receiving chemotherapy or radiation Have had surgery for your colon cancer Cognitive Impairment
Stakeholders' perspectives of collecting patient-level data on social determinants of health to identify patient needs and barriers to cancer care across the PSCI catchment area
This study will conduct one-on-one interviews with cancer patients, survivors, medical providers, and patient navigators to better understand individuals' experiences and opinions on the use of social information to improve cancer care. Social information includes one's current living situation, income, transportation needs, medical insurance coverage, social support system, and other related factors.
English or Spanish Speaking Provides care for cancer patient(s)/survivor(s) A cancer patient/survivor Current role is a cancer patient care navigator
Exclusion Criteria:
Unable to speak English or Spanish Under 18 years of age Unwilling to be audio recorded
Cancer
Email this study information to me
Contact the study team
PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma
of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243 (PSCI 18-129)
This is a Phase II drug study which is designed to examine the effects of Durvalumab on individuals with bladder cancer that has not invaded muscle tissue. Study subjects will have already been treated with one or more surgical resections and Bacillus Calmette-Guerin or BCG, and the disease has now recurred.
Histologically confirmed non-muscle invasive urothelial carcinoma of the bladder (Ta, T1, or Tis stage) on transurethral resection of bladder tumor (TURBT) obtained within 60 days of registration. ECOG (WHO) performance status 0 or 1 Age ≥ 18 years old at time of consent White blood cell count (WBC) > 3.0 K/mm3 Absolute neutrophil count (ANC) ≥ 1.5 K/mm3
Exclusion Criteria:
Subjects with muscle-invasive (i.e. T2, T3, T4), locally advanced unresectable, or metastatic urothelial carcinoma as assessed on baseline radiographic imaging obtained within 60 days prior to study registration. Subjects with another active second malignancy other than non-melanoma skin cancers and biochemical relapsed prostate cancer. Subjects that have completed all necessary therapy and are considered to be at less than 30% risk of relapse are not considered to have an active second malignancy and are eligible for enrollment. Subjects who have received the last administration of an anti-cancer therapy including chemotherapy, immunotherapy, and monoclonal antibodies ≤ 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy. Subjects who have had any prior radiation to the prostate or pelvis.